Lab-on-Chip and Research Services
At Andremacon, we are dedicated to advancing personalized and cutting-edge therapies that meet the unique needs of each patient. Through a combination of innovative technologies, groundbreaking research, and a profound understanding of disease biology, we are pioneering new approaches that promise to transform how complex medical conditions are managed and treated.
Personalized Medicine and Lab-on-Chip technology
At the heart of our pipeline is the development of cell-based personalized medicine platforms that leverage genomic profiling, molecular diagnostics, and advanced bioinformatics to tailor treatment strategies to the unique genetic makeup and molecular signatures of each patient. By identifying disease-associated biomarkers and genetic alterations, we equip researchers and clinicians with tools to deliver more accurate, targeted therapies.
Our in vitro/ex vivo patient-specific platforms allow scientists, healthcare providers, and companies to develop drug candidates more efficiently and at reduced costs. This drug platform technology serves as a foundation upon which multiple therapies can be built, thus streamlining the process of developing new treatments. Well-designed platforms accelerate drug creation by establishing a base that eliminates redundant steps.
Patient-Specific Lab-on-Chip and Research Services
The miniaturization of processes in chemistry and molecular biology has led to the emergence of Lab-on-Chip systems—microfabricated devices capable of handling minute fluid volumes. These systems simulate tissue and organ functions, offering potential to bypass traditional cell and animal testing methods. They have garnered significant interest for disease modeling and drug discovery.
At Andremacon, our Lab-on-Chip platforms support tissue-specific cancer modeling, metastasis, and tumor microenvironment studies. These platforms have broad applications for toxicity testing, disease modeling, and personalized medicine. We offer the following tools:
- Personalized Blood-Brain Barrier model
- Tissue-specific organoid cultures
- In vitro vascular vessel generation
- Endothelial cell culture from biopsies or circulating cells
- Molecular profiling
- Microfluidic systems
By integrating these platforms, we aim to enhance drug development, biomarker discovery, and predict patient-specific therapeutic responses, ultimately bringing personalized medicine closer to reality.
Drug Delivery Systems
We are also pushing the boundaries of drug delivery systems, exploring innovative methods to improve therapeutic efficacy, safety, and patient convenience. From nanoparticle-based drug carriers to implantable devices and targeted drug delivery systems, our projects involve cutting-edge approaches, including:
- Nanovesicles and functionalized liposomes
- Trojan-horse molecules to enhance targeted drug delivery and release.
These innovations aim to optimize how therapies reach their intended targets, improving clinical outcomes and reducing side effects.
